| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/27/2013 | CA2407847C Transgenic animal model of neurodegenerative disorders |
| 08/27/2013 | CA2291861C Zinc finger protein derivatives and methods therefor |
| 08/27/2013 | CA2227301C Hcv binding protein |
| 08/22/2013 | WO2013123521A1 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients |
| 08/22/2013 | WO2013123457A1 Recombinant factor viii proteins |
| 08/22/2013 | WO2013123432A2 Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| 08/22/2013 | WO2013123424A1 Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide |
| 08/22/2013 | WO2013123423A1 Purification method |
| 08/22/2013 | WO2013123305A1 Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof |
| 08/22/2013 | WO2013123267A1 Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| 08/22/2013 | WO2013123266A1 Peptidomimetic macrocycles |
| 08/22/2013 | WO2013123248A1 MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE |
| 08/22/2013 | WO2013123223A1 Enzymes and methods for cleaving n-glycans from glycoproteins |
| 08/22/2013 | WO2013123151A1 Methods of controlling tumor bioenergetics networks |
| 08/22/2013 | WO2013123094A2 Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| 08/22/2013 | WO2013123026A1 Rlip76 as a medical chemical countermeasure |
| 08/22/2013 | WO2013122979A1 Methods for treating pain associated with chronic pancreatitis |
| 08/22/2013 | WO2013122976A1 Osteopontin isoform a inhibitors and methods of use |
| 08/22/2013 | WO2013122778A1 Methods of treating and preventing diseases and disorders of the central nervous system |
| 08/22/2013 | WO2013122617A1 Factor viii compositions and methods of making and using same |
| 08/22/2013 | WO2013121428A1 ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS |
| 08/22/2013 | WO2013121416A1 Long-acting coagulation factors and methods of producing same |
| 08/22/2013 | WO2013121405A1 Oral unit dosage forms and uses of same for the treatment of gaucher disease |
| 08/22/2013 | WO2013121296A1 Erythrocyte-binding therapeutics |
| 08/22/2013 | WO2013121202A1 Treatment of skin disorders |
| 08/22/2013 | WO2013120939A1 Von willebrand factor variants having improved factor viii binding affinity |
| 08/22/2013 | WO2013093045A3 Cyclotides as immunosuppressive agents |
| 08/22/2013 | WO2013066214A3 Aerosol pharmaceutical composition of protease inhibitors and production thereof |
| 08/22/2013 | WO2013064830A3 Medical use |
| 08/22/2013 | US20130217949 Combinatorial methods and compositions for treatment of melanoma |
| 08/22/2013 | US20130217865 Tumor Specific Antibody |
| 08/22/2013 | US20130217857 Erbb interface peptidomimetics and methods of use thereof |
| 08/22/2013 | US20130217635 Novel use of erythroid differentiation regulator 1 as an agent for treating cancer |
| 08/22/2013 | US20130217633 Inhibitors of bcl-2 |
| 08/22/2013 | US20130217631 Collagen mixture and method of making the same |
| 08/22/2013 | US20130217629 Methods for making proteins containing free cysteine residues |
| 08/22/2013 | US20130217627 Therapeutic application of adiponectin in patients with ventricular fibrillation |
| 08/22/2013 | US20130217624 Composition and method for the inhibition of postoperative adhesions severity |
| 08/22/2013 | US20130217619 Linear peptide antibiotics |
| 08/22/2013 | US20130217617 Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use |
| 08/22/2013 | US20130217616 Chimeric inhibitor molecules of complement activation |
| 08/22/2013 | US20130217615 Combination treatment of major depressive disorder |
| 08/22/2013 | US20130217129 Conditioned cell culture medium compositions and methods of use |
| 08/22/2013 | US20130217116 Peptide II |
| 08/22/2013 | US20130217069 Conditioned cell culture medium compositions and methods of use |
| 08/22/2013 | US20130216630 Biomaterials for use in methods of bone replacement therapy |
| 08/22/2013 | US20130216626 Platelet-rich plasma compositions |
| 08/22/2013 | US20130216622 Modified beta-lactamases and methods and uses related thereto |
| 08/22/2013 | US20130216610 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
| 08/22/2013 | US20130216604 Polypeptide for inhibiting metastasis, uses thereof, and pharmaceutical compositions containing the same |
| 08/22/2013 | US20130216588 Insulin-gold nanocluster, pharmaceutical composition for reducing blood glucose comprising the same, and method for detecting adipose cells in tissue by using the same |
| 08/22/2013 | US20130216583 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 08/22/2013 | US20130216577 Methods And Compositions For The Dietary Management Of Autoimmune Disorders |
| 08/22/2013 | US20130216540 Modulation of the innate immune system through the trem-like transcript 2 protein |
| 08/22/2013 | US20130216537 Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss |
| 08/22/2013 | US20130216521 Dietary supplement for enhancing animal health |
| 08/22/2013 | US20130216520 Processing biomass |
| 08/22/2013 | US20130216518 Composition comprising a combination of at least one proteolytic enzyme and at least one lipolytic enzyme, for use in preventing triglyceride synthesis |
| 08/22/2013 | US20130216517 Standardized bee venom preparation |
| 08/22/2013 | US20130216516 Method for treating delayed-type hypersensitivity |
| 08/22/2013 | US20130216515 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
| 08/22/2013 | US20130216514 Compositions comprising glutathione reductase and oxidized glutathione |
| 08/22/2013 | US20130216504 Ccn3 and ccn3 peptides and analogs thereof for therapeutec uses |
| 08/22/2013 | US20130216503 Methods for Generating Cardiomyocytes |
| 08/22/2013 | US20130216500 Method of treating or retarding the development of blindness |
| 08/22/2013 | US20130216496 Methods for treating tweak-related conditions |
| 08/22/2013 | DE102012003541A1 Bacterial nanocellulose body useful e.g. as transplant for in situ cell colonization and tissue formation, comprises channel-like pore structure, interconnecting multidimensional structure, and channel-shaped cavities with open cell wall |
| 08/22/2013 | DE102012003286A1 Kombination aus Lipidtransferproteinen und Phenolderivate enthaltenden Pflanzenstoffen mit lokal-mucosaler Effizienz Combination of lipid transfer proteins and phenolic derivatives containing plant materials with locally-mucosal efficiency |
| 08/22/2013 | CA2850380A1 Agents and method for treating inflammation-related conditions and diseases |
| 08/21/2013 | EP2628747A1 Impaired wound healing compositions and treatments |
| 08/21/2013 | EP2628746A2 A process for concentration of a polypeptide |
| 08/21/2013 | EP2628488A1 Sustained-release pharmaceutical composition |
| 08/21/2013 | EP2628484A1 Platelet-rich plasma compositions |
| 08/21/2013 | EP2627674A2 Egfr-based peptides |
| 08/21/2013 | EP2627670A2 Novel n-terminally modified insulin derivatives |
| 08/21/2013 | EP2627669A1 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| 08/21/2013 | EP2627668A1 Peptides and uses |
| 08/21/2013 | EP2627355A1 Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material |
| 08/21/2013 | EP2627354A1 Suppression of a type 1 hypersensitivity immune response with an unrelated antigen |
| 08/21/2013 | EP2627350A1 Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
| 08/21/2013 | EP2627349A2 Obesity-related genes and their proteins and uses thereof |
| 08/21/2013 | EP2627348A1 Method for purification of complement factor h |
| 08/21/2013 | EP2627347A1 Uses of macrophage mannose receptor to screen compounds and uses of these compounds |
| 08/21/2013 | EP2627346A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| 08/21/2013 | EP2627320A1 Formulation comprising a type b lantibiotic |
| 08/21/2013 | EP2627201A1 Antimicrobial protein |
| 08/21/2013 | EP2627192A2 Hydrolysates of animal proteins of marine origin with neuroprotective properties |
| 08/21/2013 | EP2143437B1 Compositions and methods for the diagnosis and treatment of tumor |
| 08/21/2013 | EP1516628B1 Stable isotonic lyophilized protein formulation |
| 08/21/2013 | CN1968717B Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
| 08/21/2013 | CN103261895A Tyrosine-phosphorylated wbp2, a novel cancer target and biomarker |
| 08/21/2013 | CN103261890A Inhibitors of human ezh2, and methods of use thereof |
| 08/21/2013 | CN103261217A Soluble pd-1 variants, fusion constructs, and uses thereof |
| 08/21/2013 | CN103260649A Long lasting drug formulations |
| 08/21/2013 | CN103260647A EGFR antagonist for the treatment of heart disease |
| 08/21/2013 | CN103260637A Methods and compositions for cns delivery of heparan n-ulfatase |
| 08/21/2013 | CN103260636A Therapeutic agent for disc herniation |
| 08/21/2013 | CN103260635A Compositions and uses of materials with high antimicrobial activity and low toxicity |
| 08/21/2013 | CN103260628A Use of hyaluronan for promoting angiogenesis |
| 08/21/2013 | CN103260612A Treatment of mecp2-ssociated disorders |